Old West Investment Management LLC Increases Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Old West Investment Management LLC raised its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 617.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 340,441 shares of the biopharmaceutical company's stock after purchasing an additional 292,976 shares during the period. Amicus Therapeutics accounts for about 1.4% of Old West Investment Management LLC's holdings, making the stock its 22nd biggest position. Old West Investment Management LLC owned 0.11% of Amicus Therapeutics worth $3,636,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of FOLD. OLD Second National Bank of Aurora purchased a new position in Amicus Therapeutics during the 3rd quarter valued at about $26,000. Hazlett Burt & Watson Inc. increased its holdings in Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 1,569 shares during the period. Blue Trust Inc. increased its holdings in Amicus Therapeutics by 1,705.4% during the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 2,831 shares during the period. Arcadia Investment Management Corp MI bought a new position in Amicus Therapeutics in the 3rd quarter valued at $32,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Amicus Therapeutics during the 3rd quarter valued at $55,000.

Insider Buying and Selling at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of the company's stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $11.46, for a total transaction of $85,950.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares of the company's stock, valued at approximately $10,161,054.84. This represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders sold 30,401 shares of company stock worth $339,363. 2.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Bank of America lifted their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Thursday, October 17th. Guggenheim boosted their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Jefferies Financial Group began coverage on shares of Amicus Therapeutics in a research note on Friday, September 6th. They issued a "buy" rating and a $18.00 target price on the stock. Cantor Fitzgerald boosted their price target on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an "overweight" rating in a research report on Tuesday, November 12th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $17.63.

Amicus Therapeutics Trading Up 0.3 %

Shares of NASDAQ FOLD traded up $0.03 during midday trading on Wednesday, reaching $10.16. The company had a trading volume of 1,937,407 shares, compared to its average volume of 2,716,266. The firm's fifty day moving average price is $10.56 and its 200-day moving average price is $10.61. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. Amicus Therapeutics, Inc. has a one year low of $9.02 and a one year high of $14.57. The stock has a market cap of $3.04 billion, a PE ratio of -29.79 and a beta of 0.60.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.